Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking strategy to diabetes management. These innovative medications function by mimicking the natural actions of GLP-1, a hormone secreted by the gut in response to meals. By activating GLP-1 receptors in the pancreas, these compounds enhance insulin production and reduce g

The burgeoning landscape of innovative treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting significant weight reduction – they exhibit intriguing variat